Activin suppresses LPS-induced Toll-like receptor, cytokine and inducible nitric oxide synthase expression in normal human melanocytes by inhibiting NF-?B and MAPK pathway activation

International Journal of Molecular Medicine

Volumn 36, Issue 4, 2015, Pages 1165-1172

  Kim, Young Il ^a   Park, Seung Won ^b   Kang, In Jung ^c   Shin, Min Kyung ^c   Lee, Mu Hyoung ^c  

^a Kyung Hee University College of Medicine   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

?oll like receptor; Activin A; Cytokine; Inducible nitric oxide synthase; Normal human melanocytes; Nuclear factor ?B

Indexed keywords

ACTIVIN A; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ACTIVIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; NOS2 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MELANOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM;

ACTIVINS; CELL LINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MELANOCYTES; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; TOLL-LIKE RECEPTORS;

EID: 84940386376     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2308     Document Type: Article

References (34)

1. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP and de Kretser DM: Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 180: 155-162, 2001.
2. Marshak-Rothstein A and Rifkin IR: Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 25: 419-441, 2007.
3. Takeuchi O and Akira S: Pattern recognition receptors and inflammation. Cell 140: 805-820, 2010.
4. Akira S, Takeda K and Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680, 2001.
5. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001.
6. Barton GM and Medzhitov R: Toll-like receptor signaling pathways. Science 300: 1524-1525, 2003.
7. Kawai T and Akira S: TLR signaling. Semin Immunol 19: 24-32, 2007.
8. Lee YM, Seon MR, Cho HJ, Kim JS and Park JH: Benzyl isothiocyanate exhibits anti-inflammatory effects in murine macrophages and in mouse skin. J Mol Med Berl 87: 1251-1261, 2009.
9. Zaidi SF, Yamamoto T, Refaat A, Ahmed K, Sakurai H, Saiki I, Kondo T, Usmanghani K, Kadowaki M and Sugiyama T: Modulation of activation-induced cytidine deaminase by curcumin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter 14: 588-595, 2009.
10. Marletta MA: Approaches toward selective inhibition of nitric oxide synthase. J Med Chem 37: 1899-1907, 1994.
11. Nathan C and Xie QW: Nitric oxide synthases: Roles, tolls, and controls. Cell 78: 915-918, 1994.
12. Mathews LS: Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev 15: 310-325, 1994.
13. Mather JP, Moore A and Li RH: Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Proc Soc Exp Biol Med 215: 209-222, 1997.
14. Sugama S, Takenouchi T, Kitani H, Fujita M and Hashimoto M: Activin as an anti-inflammatory cytokine produced by microglia. J Neuroimmunol 192: 31-39, 2007.
15. Wang SY, Tai GX, Zhang PY, Mu DP, Zhang XJ and Liu ZH: Inhibitory effect of activin A on activation of lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Cytokine 42: 85-91, 2008.
16. Plonka PM, Passeron T, Brenner M, Tobin DJ, Shibahara S, Thomas A, Slominski A, Kadekaro AL, Hershkovitz D, Peters E, et al: What are melanocytes really doing all day long? Exp Dermatol 18: 799-819, 2009.
17. Tsatmali M, Ancans J and Thody AJ: Melanocyte function and its control by melanocortin peptides. J Histochem Cytochem 50: 125-133, 2002.
18. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G and Herlyn M: Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56: 853-857, 1994.
19. Ahn JH, Park TJ, Jin SH and Kang HY: Human melanocytes express functional Toll-like receptor 4. Exp Dermatol 17: 412-417, 2008.
20. Stove C, Vanrobaeys F, Devreese B, Van Beeumen J, Mareel M and Bracke M: Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition. Oncogene 23: 5330-5339, 2004.
21. Sabroe I, Read RC, Whyte MK, Dockrell DH, Vogel SN and Dower SK: Toll-like receptors in health and disease: complex questions remain. J Immunol 171: 1630-1635, 2003.
22. Cook DN, Pisetsky DS and Schwartz DA: Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5: 975-979, 2004.
23. Strober W, Murray PJ, Kitani A and Watanabe T: Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6: 9-20, 2006.
24. Yu N, Zhang S, Zuo F, Kang K, Guan M and Xiang L: Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9. J Dermatol Sci 56: 113-120, 2009.
25. Jin SH and Kang HY: Activation of toll-like receptors 1, 2, 4, 5, and 7 on human melanocytes modulate pigmentation. Ann Dermatol 22: 486-489, 2010.
26. Tsatmali M, Graham A, Szatkowski D, Ancans J, Manning P, McNeil CJ, Graham AM and Thody AJ: alpha-melanocyte-stimulating hormone modulates nitric oxide production in melanocytes. J Invest Dermatol 114: 520-526, 2000.
27. Wang R, Ghahary A, Shen YJ, Scott PG and Tredget EE: Human dermal fibroblasts produce nitric oxide and express both constitutive and inducible nitric oxide synthase isoforms. J Invest Dermatol 106: 419-427, 1996.
28. Rocha IM and Guillo LA: Lipopolysaccharide and cytokines induce nitric oxide synthase and produce nitric oxide in cultured normal human melanocytes. Arch Dermatol Res 293: 245-248, 2001.
29. Gupta SC, Sundaram C, Reuter S and Aggarwal BB: Inhibiting NF-?B activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799: 775-787, 2010.
30. Wan F and Lenardo MJ: The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res 20: 24-33, 2010.
31. Kaminska B: MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754: 253-262, 2005.
32. Yamashita N, Nakajima T, Takahashi H, Kaneoka H, Mizushima Y and Sakane T: Effects of activin A on IgE synthesis and cytokine production by human peripheral mononuclear cells. Clin Exp Immunol 94: 214-219, 1993.
33. Murase Y, Okahashi N, Koseki T, Itoh K, Udagawa N, Hashimoto O, Sugino H, Noguchi T and Nishihara T: Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A. J Cell Physiol 188: 236-242, 2001.
34. Sugatani T, Alvarez UM and Hruska KA: Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem 90: 59-67, 2003.